相似文献
1
Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.
Antimicrob Agents Chemother. 2011 May;55(5):2478-80. doi: 10.1128/AAC.01560-10. Epub 2011 Mar 14.
2
Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02326-17. Print 2018 Apr.
3
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. doi: 10.1128/AAC.01061-07. Epub 2007 Dec 10.
4
Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance.
Int J Infect Dis. 2020 Dec;101:24-28. doi: 10.1016/j.ijid.2020.09.019. Epub 2020 Sep 13.
5
Echinocandin antifungal drugs in fungal infections: a comparison.
Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000.
6
Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.
Antimicrob Agents Chemother. 2013 Jan;57(1):281-8. doi: 10.1128/AAC.01387-12. Epub 2012 Oct 31.
7
Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.
J Antimicrob Chemother. 2017 May 1;72(5):1429-1432. doi: 10.1093/jac/dkw568.
8
Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis.
Int J Infect Dis. 2019 Sep;86:142-146. doi: 10.1016/j.ijid.2019.07.008. Epub 2019 Jul 19.
9
Management of Aspergillus pleural empyema with combined systemic and intrapleural antifungal therapy in a pediatric patient: Case report.
J Infect Public Health. 2018 Mar-Apr;11(2):280-282. doi: 10.1016/j.jiph.2017.04.003. Epub 2017 May 22.
10
Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
Int J Antimicrob Agents. 2015 Dec;46(6):631-41. doi: 10.1016/j.ijantimicag.2015.08.009. Epub 2015 Sep 21.
引用本文的文献
1
In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Clades in a Neutropenic Mouse Bloodstream Infection Model.
J Fungi (Basel). 2024 Aug 29;10(9):617. doi: 10.3390/jof10090617.
2
Application and evaluation of topical amphotericin B for the treatment of respiratory fungal infections.
BMC Infect Dis. 2024 Apr 24;24(1):439. doi: 10.1186/s12879-024-09342-9.
3
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.
Mycopathologia. 2023 Dec;188(6):937-948. doi: 10.1007/s11046-023-00759-5. Epub 2023 Jul 20.
4
An Unusual Case of Candida albicans Empyema in Patient With Gastric Cancer and Colon Metastasis.
Cureus. 2023 Jan 20;15(1):e34023. doi: 10.7759/cureus.34023. eCollection 2023 Jan.
5
The outcomes of thoracoscopic decortication between fungal empyema and bacterial empyema.
BMC Infect Dis. 2023 Jan 6;23(1):8. doi: 10.1186/s12879-022-07978-z.
6
Empyema Thoracis-A Post-COVID-19 Complication.
J Fungi (Basel). 2022 Aug 30;8(9):923. doi: 10.3390/jof8090923.
7
A Case Report of -Associated Empyema Treated With Intravenous Injection and Local Thoracic Irrigation of Amphotericin B Plus Medical Thoracoscopy.
Front Public Health. 2022 Jul 6;10:914529. doi: 10.3389/fpubh.2022.914529. eCollection 2022.
8
Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes.
Open Forum Infect Dis. 2021 Apr 17;8(4):ofaa656. doi: 10.1093/ofid/ofaa656. eCollection 2021 Apr.
9
Comparison of Killing Activity of Micafungin Against Six Candida Species Isolated from Peritoneal and Pleural Cavities in RPMI-1640, 10 and 30% Serum.
Mycopathologia. 2018 Dec;183(6):905-912. doi: 10.1007/s11046-018-0302-5. Epub 2018 Oct 31.
10
Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02326-17. Print 2018 Apr.
本文引用的文献
1
A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid.
Intern Med. 2010;49(12):1163-9. doi: 10.2169/internalmedicine.49.2860. Epub 2010 Jun 15.
2
Pharmacokinetics of liposomal amphotericin B in pleural fluid.
Antimicrob Agents Chemother. 2010 Apr;54(4):1633-5. doi: 10.1128/AAC.01438-09. Epub 2010 Jan 19.
3
Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.
Antimicrob Agents Chemother. 2009 Dec;53(12):5102-7. doi: 10.1128/AAC.01042-09. Epub 2009 Sep 21.
4
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
5
Penetration of amphotericin B lipid formulations into pleural effusion.
Antimicrob Agents Chemother. 2007 Nov;51(11):4211-3. doi: 10.1128/AAC.01087-07. Epub 2007 Sep 4.
6
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.
Antimicrob Agents Chemother. 2007 Jun;51(6):2257-9. doi: 10.1128/AAC.00095-07. Epub 2007 Apr 16.
7
Pericardial and pleural diffusion of voriconazole during disseminated invasive aspergillosis: report of a case with successful outcome.
Intensive Care Med. 2006 Jun;32(6):939-40. doi: 10.1007/s00134-006-0113-x. Epub 2006 Mar 11.
8
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
J Clin Pharmacol. 2005 Dec;45(12):1373-82. doi: 10.1177/0091270005281234.
9
Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis.
Antimicrob Agents Chemother. 2004 Mar;48(3):1065. doi: 10.1128/AAC.48.3.1065.2004.
10
Echinocandin antifungal drugs.
Lancet. 2003 Oct 4;362(9390):1142-51. doi: 10.1016/S0140-6736(03)14472-8.
Zotero 插件